Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Review, H1 2016', provides in depth analysis on Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted pipeline therapeutics. 

The report provides comprehensive information on the Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37)
- The report reviews Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) Overview 7
Therapeutics Development 8
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Stage of Development 8
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Therapy Area 9
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Indication 10
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Companies 13
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Products under Development by Universities/Institutes 15
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Companies Involved in Therapeutics Development 23
Cantex Pharmaceuticals, Inc. 23
Chiesi Farmaceutici SpA 24
Kamada Ltd. 25
Polyphor Ltd. 26
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Drug Profiles 27
alpha-1 proteinase inhibitor (human) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ANV-201 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Brevenal - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CX-01 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
POL-6014 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule 2 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Dormant Projects 42
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Discontinued Products 45
Neutrophil Elastase (Human Leukocyte Elastase or Elastase-2 or EC 3.4.21.37) - Featured News & Press Releases 46
Jun 15, 2016: Shire and Kamada announce FDA approval of expanded label for self-infusion of Glassia for the treatment of emphysema due to severe AAT deficiency 46
May 25, 2016: Kamadas Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform 47
Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 47
Mar 28, 2016: Kamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency 49
Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia 51
Jan 06, 2016: Kamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease 51
Dec 02, 2015: Kamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes 52
Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I 53
Jul 06, 2015: Kamada Announces Publication in Pediatric Diabetes 54
Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 55
Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01 56
May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting 56
May 06, 2015: Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin During the American Thoracic Society 2015 International Conference 57
Apr 01, 2015: Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary Alpha-1 Proteinase Inhibitor 58
Mar 23, 2015: Kamada Awarded European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 18
Number of Products by Stage and Route of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 22
Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 23
Pipeline by Chiesi Farmaceutici SpA, H1 2016 24
Pipeline by Kamada Ltd., H1 2016 25
Pipeline by Polyphor Ltd., H1 2016 26
Dormant Projects, H1 2016 42
Dormant Projects (Contd..1), H1 2016 43
Dormant Projects (Contd..2), H1 2016 44
Discontinued Products, H1 2016 45